Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial

OBJECTIVES: Vascular endothelial growth factor (VEGF) has been shown to be overexpressed in several studies of hepatocellular carcinoma (HCC). Cediranib is a potent inhibitor of VEGF signaling. We assessed the efficacy and toxicity of cediranib in patients with HCC. METHODS: Twenty-eight patients wi...

Full description

Saved in:
Bibliographic Details
Main Authors: Alberts, Steven R., Fitch, Tom R., Kim, George P., Morlan, Bruce W., Dakhil, Shaker R., Gross, Howard M., Nair, Suresh
Format: Artigo
Language:Inglês
Published: 2012
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3126867/
https://ncbi.nlm.nih.gov/pubmed/21422991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0b013e3182118cdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items